Skip to main content
Top
Published in: Radiation Oncology 1/2018

Open Access 01-12-2018 | Research

A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using 125I COMS plaques

Authors: Yongsook C. Lee, Shih-Chi Lin, Yongbok Kim

Published in: Radiation Oncology | Issue 1/2018

Login to get access

Abstract

Background

It has been reported that proximity of the tumor to the optic disc and macula, and radiation dose to the critical structures are substantial risk factors for vision loss following plaque brachytherapy. However, there is little dosimetry data published on this. In this study, therefore, the relationship between distance from tumor margin and radiation dose to the optic disc and macula in ocular brachytherapy using 125I Collaborative Ocular Melanoma Study (COMS) plaques was comprehensively investigated. From the information, this study aimed to allow for estimation of optic disc dose and macula dose without treatment planning.

Methods

An in-house brachytherapy dose calculation program utilizing the American Association of Physicists in Medicine Task Group-43 U1 formalism with a line source approximation in a homogenous water phantom was developed and validated against three commercial treatment planning systems (TPS). Then optic disc dose and macula dose were calculated as a function of distance from tumor margin for various tumor basal dimensions for seven COMS plaques (from 10 mm to 22 mm in 2 mm increments) loaded with commercially available 125I seeds models (IAI-125A, 2301 and I25.S16). A prescribed dose of 85 Gy for an irradiation time of 168 h was normalized to a central-axis depth of 5 mm. Dose conversion factors for each seed model were obtained by taking ratios of total reference air kerma per seed at various prescription depths (from 1 mm to 10 mm in 1 mm intervals) to that at 5 mm.

Results

The in-house program demonstrated relatively similar accuracy to commercial TPS. Optic disc dose and macula dose decreased as distance from tumor margin and tumor basal dimension increased. Dose conversion factors increased with increasing prescription depth. There existed dose variations (<8%) among three 125I seed models. Optic disc dose and macula dose for each COMS plaque and for each seed model are presented in a figure format. Dose conversion factors for each seed model are presented in a tabular format.

Conclusions

The data provided in this study would enable clinicians in any clinic using 125I COMS plaques to estimate optic disc dose and macula dose without dose calculations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fabian ID, Tomkins-Netzer O, Stoker I, Arora AK, Sagoo MS, Cohen VM. Secondary enucleations for uveal melanoma: a 7-year retrospective analysis. Am J Ophthalmol. 2015;160(6):1104–10 e1.CrossRef Fabian ID, Tomkins-Netzer O, Stoker I, Arora AK, Sagoo MS, Cohen VM. Secondary enucleations for uveal melanoma: a 7-year retrospective analysis. Am J Ophthalmol. 2015;160(6):1104–10 e1.CrossRef
2.
go back to reference Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT, et al. The American brachytherapy society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56(2):544–55.CrossRef Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT, et al. The American brachytherapy society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56(2):544–55.CrossRef
3.
go back to reference Chiu-Tsao ST, Astrahan MA, Finger PT, Followill DS, Meigooni AS, Melhus CS, et al. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of task group 129 by the AAPM and ABS. Med Phys. 2012;39(10):6161–84.CrossRef Chiu-Tsao ST, Astrahan MA, Finger PT, Followill DS, Meigooni AS, Melhus CS, et al. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of task group 129 by the AAPM and ABS. Med Phys. 2012;39(10):6161–84.CrossRef
4.
go back to reference Tseng V, Coleman A, Zhang Z, McCannel T. Complications from plaque versus proton beam therapy for choroidal melanoma: a qualitative systematic review. J Cancer Ther. 2016;7(3):169–85.CrossRef Tseng V, Coleman A, Zhang Z, McCannel T. Complications from plaque versus proton beam therapy for choroidal melanoma: a qualitative systematic review. J Cancer Ther. 2016;7(3):169–85.CrossRef
5.
go back to reference Sagoo MS, Shields CL, Mashayekhi A, Freire J, Emrich J, Reiff J, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma overhanging the optic disc in 141 consecutive patients. Arch Ophthalmol. 2008;126(11):1515–22.CrossRef Sagoo MS, Shields CL, Mashayekhi A, Freire J, Emrich J, Reiff J, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma overhanging the optic disc in 141 consecutive patients. Arch Ophthalmol. 2008;126(11):1515–22.CrossRef
6.
go back to reference Finger PT. Finger’s “slotted” eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumours. Br J Ophthalmol. 2007;91(7):891–4.CrossRef Finger PT. Finger’s “slotted” eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumours. Br J Ophthalmol. 2007;91(7):891–4.CrossRef
7.
go back to reference Berry JL, Dandapani SV, Stevanovic M, Lee TC, Astrahan M, Murphree AL, et al. Outcomes of choroidal melanomas treated with eye physics: a 20-year review. JAMA Ophthalmol. 2013;131(11):1435–42.CrossRef Berry JL, Dandapani SV, Stevanovic M, Lee TC, Astrahan M, Murphree AL, et al. Outcomes of choroidal melanomas treated with eye physics: a 20-year review. JAMA Ophthalmol. 2013;131(11):1435–42.CrossRef
8.
go back to reference Karlsson M, Nilsson J, Lundell M, Carlsson TA. Monte Carlo dosimetry of the eye plaque design used at the St. Erik eye hospital for (125)I brachytherapy. Brachytherapy. 2014;13(6):651–6.CrossRef Karlsson M, Nilsson J, Lundell M, Carlsson TA. Monte Carlo dosimetry of the eye plaque design used at the St. Erik eye hospital for (125)I brachytherapy. Brachytherapy. 2014;13(6):651–6.CrossRef
9.
go back to reference Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219–28.CrossRef Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219–28.CrossRef
10.
go back to reference Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108(2):348–66.CrossRef Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108(2):348–66.CrossRef
11.
go back to reference Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, et al. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients. Ophthalmology. 2002;109(10):1838–49.CrossRef Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, et al. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients. Ophthalmology. 2002;109(10):1838–49.CrossRef
12.
go back to reference Finger PT, Chin KJ, Duvall G. Palladium-103 for Choroidal Melanoma Study G. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 2009;116(4):790–6 6 e1.CrossRef Finger PT, Chin KJ, Duvall G. Palladium-103 for Choroidal Melanoma Study G. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 2009;116(4):790–6 6 e1.CrossRef
13.
go back to reference Sagoo MS, Shields CL, Emrich J, Mashayekhi A, Komarnicky L, Shields JA. Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases. JAMA Ophthalmol. 2014;132(6):697–702.CrossRef Sagoo MS, Shields CL, Emrich J, Mashayekhi A, Komarnicky L, Shields JA. Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases. JAMA Ophthalmol. 2014;132(6):697–702.CrossRef
15.
go back to reference Rivard MJ, Chiu-Tsao ST, Finger PT, Meigooni AS, Melhus CS, Mourtada F, et al. Comparison of dose calculation methods for brachytherapy of intraocular tumors. Med Phys. 2011;38(1):306–16.CrossRef Rivard MJ, Chiu-Tsao ST, Finger PT, Meigooni AS, Melhus CS, Mourtada F, et al. Comparison of dose calculation methods for brachytherapy of intraocular tumors. Med Phys. 2011;38(1):306–16.CrossRef
16.
go back to reference Rivard MJ, Coursey BM, DeWerd LA, Hanson WF, Huq MS, Ibbott GS, et al. Update of AAPM task group no. 43 report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31(3):633–74.CrossRef Rivard MJ, Coursey BM, DeWerd LA, Hanson WF, Huq MS, Ibbott GS, et al. Update of AAPM task group no. 43 report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31(3):633–74.CrossRef
17.
go back to reference Rivard MJ, Butler WM, DeWerd LA, Huq MS, Ibbott GS, Meigooni AS, et al. Supplement to the 2004 update of the AAPM task group no. 43 report. Med Phys. 2007;34(6):2187–205.CrossRef Rivard MJ, Butler WM, DeWerd LA, Huq MS, Ibbott GS, Meigooni AS, et al. Supplement to the 2004 update of the AAPM task group no. 43 report. Med Phys. 2007;34(6):2187–205.CrossRef
18.
go back to reference American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address pec, Committee AO. The American brachytherapy society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.CrossRef American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address pec, Committee AO. The American brachytherapy society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.CrossRef
19.
go back to reference Thomson RM, Rogers DW. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models. Med Phys. 2010;37(1):368–76.CrossRef Thomson RM, Rogers DW. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models. Med Phys. 2010;37(1):368–76.CrossRef
20.
go back to reference Hegde JV, McCannel TA, McCannel CA, Lamb J, Wang P-C, Veruttipong D, et al. Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy. Graefes Arch Clin Exp Ophthalmol. 2017;255(9):1843–50.CrossRef Hegde JV, McCannel TA, McCannel CA, Lamb J, Wang P-C, Veruttipong D, et al. Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy. Graefes Arch Clin Exp Ophthalmol. 2017;255(9):1843–50.CrossRef
Metadata
Title
A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using 125I COMS plaques
Authors
Yongsook C. Lee
Shih-Chi Lin
Yongbok Kim
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-018-1166-z

Other articles of this Issue 1/2018

Radiation Oncology 1/2018 Go to the issue